This study seeks to evaluate the therapeutic potential of targeting glycolysis, FAO, and HIF‐1α in silica‐induced pulmonary fibrosis, thus highlighting the potential of HIF‐1α‐mediated metabolic dysregulation as a promising therapeutic target for experimental pulmonary fibrosis. Here, HIF1A is linked to pulmonary fibrosis.